Interestingly, PD-1/PD-L1 inhibitors can enhance the anti-cancer effect of RAD001 in renal cancer cells [28,29], and the drug targeting the PD-1/PD-L1 axis combined with autophagy inhibitor provides a new opportunity for tumor treatment. This evidence concerns the gene CD274 and renal carcinoma.